TiNivo 2 Trial Results

Update from ESMO

Data from the TiNivo-2 trial was presented on September 13, 2024, at the European Society for Medical Oncology (ESMO) conference in Barcelona. Below is a recap and discussion of the data that was presented. The thoughts and views that I am sharing about this trial are my own personal opinions. I am not a doctor and this is not medical advice.

Background

Most patients diagnosed with metastatic RCC will get first line treatment with one of the following combinations:

Many patients want to stay on immunotherapy treatment, even if their disease progresses on one of these combination treatments. Many doctors have been willing to continue infusion immunotherapy agents beyond progression.

The TiNivo2 trial sought to help answer this question and provide the data to support continuation.

Trial Design

Patients with metastatic RCC who had progressed on treatment with immunotherapy were enrolled in the trial. 

Arm 1: Patients were treated with tivozanib (Fotivda – targeted oral agent) combined with nivolumab (Opdivo – immunotherapy).  

Arm 2: Patients were given tivozanib (Fotivda – targeted oral agent) alone.  

Results

Patients in the combination arm had a median progression free survival of 5.7 months.

Patients in the control arm, treated with single agent tivozanib, had a median progression free survival of 7.4 months.

Bottom Line: Patients who continued with immunotherapy did worse than patients who received single agent treatment with tivozanib.  

The trial also showed that patients who had most recently been treated with Immunotherapy (IO) and had fewer lines of therapy had an even longer progression free survival, indicating that tivozanib (Fotivda) might be a good drug to consider as a second line treatment.

Data from this trial was published in The Lancet with the following conclusion:

This is the second trial to show that continuing treatment with immunotherapy following progression results in worse outcomes.  

The CONTACT03 trial testing combination atezolizumab (immunotherapy)+ cabozantinib compared to cabozantinib alone also found that patients who continued getting immunotherapy had shorter progression free survival compared to patients who were treated with single agent targeted treatment. 

What does this mean?

Following CONTACT03, many specialists were already changing their practice to stop using immunotherapy following progression. However, many community oncologists had not stopped doing so and even among specialists, there was some discord.  

The TiNIVO trial will likely be more of a confirmatory event. We could see changes to the NCCN guidelines and other practice recommendations taking a more definitive stance on this topic. 

Does this mean that patients can NEVER get treated with immunotherapy again if you previously progressed?  

There is still a great deal of uncertainty about how to sequence treatments and when to rechallenge drugs. No doubt, doctors and patients will continue to experiment with various strategies.  

What this trial does help to clarify is that continuing to use immunotherapy after first-line progression should not be standard of care. 

Lost Password

Register

Subscribe for updates!